Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

Urovant Sciences

Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions. Urovant’s lead therapeutic candidate is vibegron, a potent and selective ß3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron (formerly MK-4618) from Merck. Urovant intends to develop treatments for additional urologic diseases. *

 

Period Start 2017-08-11 existent
  Group Sumitomo (Group)
Products Industry urological drug
  Industry 2 vibegron (formerly MK-4618)
Person Person Katkin, Keith A. (Roivant Sciences 201709– CEO of Urovant Sciences before CEO of Avanir Pharmaceuticals)
     
  City n. a. 
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Roivant Sciences GmbH. (9/18/17). "Press Release: Urovant Sciences Appoints Keith A. Katkin as Chief Executive Officer". Basel.
     
   
Record changed: 2019-11-03

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Sumitomo (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top